Combining docetaxel and/or doxorubicin with a TKT inhibitor enhances the sensitivity of breast cancer cells to these two chemotherapeutic agents, thereby exerting a more potent inhibitory effect on cell proliferation [45]. Here, TKT is linked to breast carcinoma.